A-Alpha Bio
A-Alpha Bio develops biotechnology platforms that use synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Its AlphaSeq platform enables rapid, quantitative measurement of millions of protein binding affinities, while AlphaBind predicts binding strength from sequence using a large protein interaction database. The company partners with pharmaceutical organizations and runs in-house therapeutic programs to support the discovery and development of novel medicines.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2017
- Type
- Corporation Seattle business license
- Employees
- 50
- Registered name
- A Alpha Bio Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
- Founders
- David Younger, PhD, Randolph Lopez, PhD
Is this your organization? Claim it
Members see A-Alpha Bio's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
David Younger Executive Officer, Director, Chief Executive Officer & Co-Founder
-
Randolph Lopez Chief Technology Officer & Co-Founder